Hôpital Avicenne

Running trials

• Not yet recruiting

  Tracheal Replacement Using A Cryopreserved Aortic Allograft For R0 Resection In Locally Advanced Thyroid Cancer (TRITON 02 Tracheal Replacement In ThyrOid caNcer)

  NCT07823686· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)

  NCT07852442· Centre Hospitalier Universitaire de la Guadeloupe· Source

• Not yet recruiting

  Acute Kidney Injury : Long-term Renal and Cardiovascular Prognosis and Biomarker-based Risk Assessment

  NCT07596407· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction

  NCT07445737· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Recruiting

  Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)

  NCT07317102· Insulet Corporation· Source

• Recruiting

  Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

  NCT07124858· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Validation of French PHQ-4 and PC-PTSD-5 Screening Scales

  NCT07396623· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Movement Sonification as an add-on to Immediate Post-event Psychotherapeutic Intervention in the Management of Acute Stress Disorder: a Feasibility and Acceptability Study

  NCT07307937· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

  NCT07082452· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Active, not recruiting

  French Prospective Multicentric Study in Real World

  NCT07039942· Insulet Corporation· Source

• Recruiting

  INNODIA Family & Friends Early-Stage T1D Detection Protocol

  NCT07118098· INNODIA iVZW· Source

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Calluna Pharma AS· Source

• Recruiting

  Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C

  NCT06755632· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 antiviral treatment relief strategies, in patients co-infected with the HIV-1 and HBV viruses

  2023-508634-34-00· Phase 2· Inserm· Source

• Recruiting

  MODULO

  NCT06774872· Phase 3· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

• Recruiting

  MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER”

  2023-508201-25-00· Phase 2· Centre De Lutte Contre Le Cancer Eugene Marquis· Source

• Recruiting

  Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

  NCT06551272· Phase 2· Center Eugene Marquis· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Recruiting

  Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

  NCT06681012· Devintec Sagl· Source

• Active, not recruiting

  Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

  NCT06513312· Phase 2· Gilead Sciences· Source

• Recruiting

  A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis.

  2023-506642-23-01· Phase 2· Molecure S.A.· Source

• Recruiting

  Effects of Yoga Therapy in Rehabilitation Compared to Physiotherapy in Moderate Axial Spondyloarthritis (axSPA)

  NCT06083090· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

  2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

  2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  The French Gut-colo

  NCT06174233· Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

  NCT06042478· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions

  NCT05622071· Phase 2· UNICANCER· Source

• Active, not recruiting

  Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

  NCT05768711· Phase 2· Groupe Francophone des Myelodysplasies· Source

• Active, not recruiting

  A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

  NCT05199051· Phase 2· Centre Antoine Lacassagne· Source

• Recruiting

  Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

  NCT05580861· Phase 1/2· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

  NCT05260528· Phase 2· Centre Hospitalier Universitaire de Nice· Source

• Recruiting

  Tuberculosis Cohort Avicenne Hospital

  NCT05539014· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Prognosis of Patients Who Presented With a State of Extreme Agitation.

  NCT05632419· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings

  NCT05590702· French Innovative Leukemia Organisation· Source

• Recruiting

  BeAT1D: Benign Autoimmunity and Type 1 Diabetes

  NCT05139784· Institut National de la Santé Et de la Recherche Médicale, France· Source

• Recruiting

  Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

  NCT04935853· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Recruiting

  Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

  NCT04777916· Acute Leukemia French Association· Source

• Recruiting

  A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  NCT05131022· Phase 1· Nurix Therapeutics, Inc.· Source

• Recruiting

  The Patient Cohort of the National Center for Precision Medicine in Leukemia

  NCT05326919· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

  NCT05246345· University Hospital, Clermont-Ferrand· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

  NCT05211895· Phase 3· AstraZeneca· Source

• Active, not recruiting

  STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT04963946· Phase 2· French Innovative Leukemia Organisation· Source

Showing 50 of 68.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia6 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Hepatitis B3 recruiting
• Liver and biliary tract cancer3 recruiting
• Lung cancer3 recruiting
• Type 1 diabetes3 recruiting
• Childhood cancers2 recruiting
• Colorectal cancer2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• HIV2 recruiting
• Myelodysplastic syndromes2 recruiting
• Ankylosing spondylitis1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Epidermolysis bullosa1 recruiting
• Follicular lymphoma1 recruiting
• Irritable bowel syndrome1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Neurofibromatosis type 11 recruiting
• Pancreatic cancer1 recruiting
• Sarcoidosis1 recruiting
• Sickle cell disease1 recruiting
• Thyroid cancer1 recruiting
• Tuberculosis1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.

  NCT04777851· Phase 3· Translational Research In Oncology· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· AstraZeneca· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration

  NCT06174181· Direction Centrale du Service de Santé des Armées· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

  2022-502828-42-00· Phase 2· Genentech Inc.· Source

• Active, not recruiting

  Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

  NCT05883644· Phase 3· AstraZeneca· Source

• Terminated

  AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine

  NCT05324852· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER

  NCT05448677· Phase 2· Centre Hospitalier Universitaire De Grenoble· Source

• Completed

  Improving FAMily Members' Experience in the ICU

  NCT05461521· Nantes University Hospital· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Pfizer· Source

• Completed

  Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

  NCT05415137· Phase 3· aTyr Pharma, Inc.· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

  NCT05323591· Alfasigma S.p.A.· Source

• Completed

  Tamibarotene/Venetoclax/Azacitidine in Previously Untreated Patients Selected for RARA-positive AML (SELECT-AML-1)

  NCT04905407· Phase 2· Syros Pharmaceuticals Inc.· Source

• Completed

  Interrupters of VAscular daMAge in Malignant Hypertension

  NCT04991077· Centre Hospitalier de PAU· Source

• Completed

  Description of the Reasons for Hospitalization of Patients With Parkinson's Disease Following Admission Through the Adult Emergency Department

  NCT07439926· Assistance Publique - Hôpitaux de Paris· Source

• Terminated

  A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

  NCT04927247· Phase 3· Pfizer· Source

• Completed

  [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

  NCT04265209· Phase 3· GE Healthcare· Source

• Completed

  Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor

  NCT05070208· Acute Leukemia French Association· Source

• Completed

  Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients

  NCT04802954· IHU Strasbourg· Source

• Completed

  Preference-based Tools for Smoking Cessation Among Disadvantaged Smokers, a Pragmatic Randomised Controlled Trial

  NCT04654585· Société de Formation Thérapeutique du Généraliste - Recherche· Source

• Completed

  A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT04497597· AbbVie· Source

• Completed

  A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

  NCT04266795· Phase 2· Takeda· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Active, not recruiting

  Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04384484· Phase 3· ADC Therapeutics S.A.· Source

• Completed

  Management of Progressive Disease in Idiopathic Pulmonary Fibrosis

  NCT03939520· Phase 4· Hospices Civils de Lyon· Source

• Completed

  Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

  NCT04233879· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Microvesicles and Monocytes to Predict Mortality of Patients with Cirrhosis

  NCT03837444· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology

  NCT03498183· Phase 2/3· Nantes University Hospital· Source

• Completed

  Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

  NCT03445845· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source

• Active, not recruiting

  A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

  NCT03778957· Phase 3· AstraZeneca· Source

• Completed

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· Phase 3· Arog Pharmaceuticals, Inc.· Source

• Completed

  Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia

  NCT03415035· AbbVie· Source

• Completed

  Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

  NCT03227419· Phase 4· Lille Catholic University· Source

• Completed

  Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

  NCT03249870· Phase 2· Versailles Hospital· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Incyte Corporation· Source

• Completed

  Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening

  NCT02738359· Hôpital Edouard Herriot· Source

• Completed

  Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

  NCT02820857· Phase 2· Hospices Civils de Lyon· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Groupe Francophone des Myelodysplasies· Source

• Completed

  SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

  NCT02117167· Phase 2· UNICANCER· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Sarcoidosis13 works · 2 trials
• Idiopathic pulmonary fibrosis11 works · 6 trials
• Chronic lymphocytic leukaemia8 works · 6 trials